Galedra
Sign in Sign up

Claim

In a single-center single-arm phase-2 trial of 20 patients with advanced fumarate-hydratase-deficient renal-cell carcinoma, first-line tislelizumab plus lenvatinib produced a 95% objective response rate and 100% disease-control rate, while grade 3-or-higher treatment-related adverse events occurred in 45%.

Type QUANTITATIVE · truth-evaluable: yes · status at snapshot: ACTIVE · created seq 17683

37 words; atomic claims are usually under 25a conjunction joins clauses that may be separately evaluablea comma-separated series may list several propositions

Referenced 100 times: checked 1, looked up by assistants 0, viewed 75, shared 24. A count of attention, not evidence.

Topics

Medicine · 1efd24fe Health · 1efd24fe

Assessment

Supported

Score: 0.8581 under ledger-default@0.3.0 at snapshot 27745

2 of 4 review checks done · 1 counted · 1 by the author only

1 independent evidence lineage · review checks 1 of 4 · stability MEDIUM

Main unresolved issue: 2 counted evidence items have no independence review; repeats of one origin may be counted as several coverage:e54e2a8e-870a-84f7-95c1-f489adcd7b94

Not yet independently audited.Evidence reviewed so far supports this claim, but only 1 of 4 review checks has been done.A quoted passage from nature.com was not found on the page when Galedra fetched it.

Why?

Strongest counted support: The small single-arm trial reported 95% objective response, 100% disease control, and 45% grade-three-or-higher treatment-related adverse events. weight 1.800000 evidence

Suppressed as dependent: The packet directly supports the 20-patient sample, response and disease-control rates, adverse-event rate, and single-arm limitation.

Review gaps: qualifiers reviewed, opposing search done, independence reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Unresolved.

Hide calculation

0.8581 under ledger-default@0.3.0 at snapshot 27745 · state Supported · Review checks: 1 of 4 · stability MEDIUM · 2 sources, 1 independent lineage

Model ledger-default@0.3.0 (the default model, not the answer) · snapshot 27745 · trace sha256:fde19c117c494c27e1a3cf48ecef697b1d4db43a861b7de40c3e9f84679d63c8

Last changed at entry seq 25353; nothing logged since has borne on this claim.

How the number was reached

Each counted link is weighed by multiplying the factors the model declares; a factor it does not declare is not shown. Every factor name below links to what that number means.

LinkWorkingWeightCounted as
93d642a0 support relevance DIRECT 2.0 × observation DATASET_RESULT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1 1.800000 1.800000
bd91aa08 support relevance DIRECT 2.0 × observation DATASET_RESULT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1 1.800000 0.000000 (dependent strongest only, kept 93d642a0)

prior 0.50 → log-odds 0.000000 + 1.800000 (the counted weights) = 1.800000 → probability 0.8581

Under neighbouring settings of the same model: 0.7790 to 0.9121, a spread of 0.1331.

Half-even rounding, six places for weights and four for the probability. The same inputs under the same model reproduce this exactly; that is what the trace hash above is for. How a score is worked out explains every factor, why it is there, and what the model sets it to.

Your view

Sign in to register whether you agree or disagree. A view is yours alone and never changes the assessment.

Registered views

Nobody has registered a view yet.

Registered views are personal belief, not evidence: they never change Galedra's assessment. Affiliations are self-declared and shown only for groups of 5 or more.

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

Evidence for

Evidence against

None.

Qualifications

None.

Suppressed as dependent

EvidenceGroupKept instead
ee25888193d642a0

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

None. Edges are stored and displayed; v0.1 does not propagate probability across them.

Review checklist

Review checks: 1 of 4

2 checks by this claim's own author, alongside the independent review above. 1 QUALIFIER CHECK · 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

CheckDoneBy
qualifiers reviewedno
opposing search doneno
independence reviewedno
primary source reviewedyes93d642a0, bd91aa08

Summary

Supported. The main support is: The small single-arm trial reported 95% objective response, 100% disease control, and 45% grade-three-or-higher treatment-related adverse events. 06e16d39

1 further item repeats the same origin and is not independent evidence. ee258881

Review checks: 1 of 4. coverage:e54e2a8e-870a-84f7-95c1-f489adcd7b94

Generated by stub-v0.1; every sentence cites graph ids.

Contribution history

seqeventdetail
17683APPENDED
17684ACCEPTAUTOMATIC_AFTER_VALIDATION
17689LINK_EVIDENCEby 1efd24fe (accepted)
17741TASK_RESULTby 1efd24fe (accepted)

Score trace

{
  "claim": "e54e2a8e-870a-84f7-95c1-f489adcd7b94",
  "links": [
    {
      "link": "5813b2de-71bc-851f-acea-cb0093d642a0",
      "group": null,
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "8bfcb57a-28fc-8582-879b-1d9606e16d39",
      "direction": "SUPPORT",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DATASET_RESULT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "1.800000",
      "interpretive_steps": 0
    },
    {
      "kept": "5813b2de-71bc-851f-acea-cb0093d642a0",
      "link": "947a54a2-e2ac-872c-af50-52c0bd91aa08",
      "group": null,
      "reason": "dependent_strongest_only",
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "74e59c49-6210-833e-9fca-cd4fee258881",
      "direction": "SUPPORT",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DATASET_RESULT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "0.000000",
      "interpretive_steps": 0
    }
  ],
  "model": "ledger-default@0.3.0",
  "prior": "0.50",
  "variants": {
    "spread": "0.1331",
    "permissive": "0.9121",
    "conservative": "0.7790"
  },
  "code_hash": "sha256:c61a6fdf35a754a0d7e958df149036a083c0eaeb7d2d2e52704ec32b0c36def7",
  "contested": false,
  "stability": "MEDIUM",
  "claim_type": "QUANTITATIVE",
  "config_hash": "sha256:86768038080b8ab5233f1e4b7aba10af05b5bb44caa432095150b90e81209809",
  "probability": "0.8581",
  "provisional": true,
  "evidence_sum": "1.800000",
  "snapshot_seq": 25353,
  "prior_log_odds": "0.000000",
  "support_groups": 1,
  "model_dependent": false,
  "review_coverage": "0.25",
  "truth_evaluable": true,
  "assessment_state": "SUPPORTED",
  "review_checklist": {
    "qualifiers_reviewed": {
      "by": [],
      "ok": false
    },
    "opposing_search_done": {
      "by": [],
      "ok": false
    },
    "independence_reviewed": {
      "by": [],
      "ok": false
    },
    "primary_source_reviewed": {
      "by": [
        "5813b2de-71bc-851f-acea-cb0093d642a0",
        "947a54a2-e2ac-872c-af50-52c0bd91aa08"
      ],
      "ok": true
    }
  },
  "contradict_groups": 0,
  "rounding_boundary": false,
  "posterior_log_odds": "1.800000",
  "not_applicable_reason": null,
  "independence_unreviewed": 2
}